Assessment of copy number status of chromosomes 6 and 11 by FISH provides independent prognostic information in primary melanoma

American Journal of Surgical Pathology

Volumn 35, Issue 8, 2011, Pages 1146-1150

  North, Jeffrey P ^a,b   Vetto, John T ^a   Murali, Rajmohan ^c   White, Kevin P ^a   White Jr , Clifton R ^a   Bastian, Boris C ^b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

ambiguity; FISH; fluorescent in situ hybridization; melanoma; overdiagnosis; prognosis

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INVASION; CHROMOSOME 11; CHROMOSOME 6; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; GENOTYPE; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; MELANOMA; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK; RISK ASSESSMENT; RISK FACTOR; SKIN TUMOR; TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 6; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; ODDS RATIO; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SKIN NEOPLASMS; TIME FACTORS; YOUNG ADULT;

EID: 79961029844     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318222a634     Document Type: Article

References (22)

1. Bastian BC, Olshen AB, LeBoit PE, et al. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol. 2003; 163:1765-1770. (Pubitemid 37310008)
2. Busam KJ, Fang Y, Jhanwar SC, et al. Distinction of conjunctival melanocytic nevi from melanomas by fluorescence in situ hybridization. J Cutan Pathol. 2010;37:196-203.
3. Clemente C, Bettio D, Venci A, et al. A fluorescence in situ hybridization (FISH) procedure to assist in differentiating benign from malignant melanocytic lesions. Pathologica. 2009;101:169-174.
4. Corona R, Mele A, Amini M, et al. Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol. 1996;14:1218-1223. (Pubitemid 26105529)
5. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135-2147. (Pubitemid 41653105)
6. Dalton SR, Gerami P, Kolaitis NA, et al. Use of fluorescence in situ hybridization (FISH) to distinguish intranodal nevus from metastatic melanoma. Am J Surg Pathol. 2010;34:231-237.
7. Farmer ER, Gonin R, Hanna MP. Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol. 1996;27:528-531. (Pubitemid 26187274)
8. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363: 809-819.
9. Gerami P, Jewell SS, Morrison LE, et al. Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol. 2009;33:1146-1156.
10. Gerami P, Wass A, Mafee M, et al. Fluorescence in situ hybridization for distinguishing nevoid melanomas from mitotically active nevi. Am J Surg Pathol. 2009;33:1783-1788.
11. Gerami P, MafeeM, Lurtsbarapa T, et al. Sensitivity of fluorescence in situ hybridization for melanoma diagnosis using RREB1,MYB, Cep6, and 11q13 probes in melanoma subtypes. Arch Dermatol. 2010;146: 273-278.
12. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
13. Kempf W, Haeffner AC, Mueller B, et al. Experts and gold standards in dermatopathology: qualitative and quantitative analysis of the self-assessment slide seminar at the 17th colloquium of the International Society of Dermatopathology. Am J Dermatopathol. 1998;20:478-482. (Pubitemid 28463415)
14. Levell NJ, Beattie CC, Shuster S, et al. Melanoma epidemic: a midsummer night's dream? Br J Dermatol. 2009;161:630-634.
15. Lodha S, Saggar S, Celebi JT, et al. Discordance in the histopathologic diagnosis of difficult melanocytic neoplasms in the clinical setting. J Cutan Pathol. 2008;35:349-352. (Pubitemid 351363772)
16. Morey AL, Murali R, McCarthy SW, et al. Diagnosis of cutaneous melanocytic tumours by four-colour fluorescence in situ hybridization. Pathology. 2009;41:383-387.
17. Newman MD, Lertsburapa T, Mirzabeigi M, et al. Fluorescence in situ hybridization as a tool for microstaging in malignant melanoma. Mod Pathol. 2009;22:989-995.
18. Santillan AA, Messina JL, Marzban SS, et al. Pathology review of thin melanoma and melanoma in situ in a multidisciplinary melanoma clinic: impact on treatment decisions. J Clin Oncol. 2010;28:481-486.
19. Shoo BA, Sagebiel RW, Kashani-Sabet M. Discordance in the histopathologic diagnosis of melanoma at a melanoma referral center. J Am Acad Dermatol. 2010;62:751-756.
20. Veenhuizen KC, De Wit PE, Mooi WJ, et al. Quality assessment by expert opinion in melanoma pathology: experience of the pathology panel of the dutch melanoma working party. J Pathol. 1997;182: 266-272. (Pubitemid 27285778)
21. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102:605-613.
22. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ. 2005;331:481.